Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Enhanced protection of C57 BL/6 vs Balb/c mice to melanoma liver metastasis is mediated by NK cells.

Foerster F, Boegel S, Heck R, Pickert G, Rüssel N, Rosigkeit S, Bros M, Strobl S, Kaps L, Aslam M, Diken M, Castle J, Sahin U, Tuettenberg A, Bockamp E, Schuppan D.

Oncoimmunology. 2017 Dec 26;7(4):e1409929. doi: 10.1080/2162402X.2017.1409929. eCollection 2018.

2.

Protein corona-mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses.

Shen L, Tenzer S, Storck W, Hobernik D, Raker VK, Fischer K, Decker S, Dzionek A, Krauthäuser S, Diken M, Nikolaev A, Maxeiner J, Schuster P, Kappel C, Verschoor A, Schild H, Grabbe S, Bros M.

J Allergy Clin Immunol. 2018 Jan 31. pii: S0091-6749(18)30121-0. doi: 10.1016/j.jaci.2017.08.049. [Epub ahead of print]

3.

Translating Science into Survival: Report on the Third International Cancer Immunotherapy Conference.

Diken M, Chu KK, Brodsky AN.

Cancer Immunol Res. 2018 Jan;6(1):10-13. doi: 10.1158/2326-6066.CIR-17-0656.

PMID:
29298782
4.

FBXO32 promotes microenvironment underlying epithelial-mesenchymal transition via CtBP1 during tumour metastasis and brain development.

Sahu SK, Tiwari N, Pataskar A, Zhuang Y, Borisova M, Diken M, Strand S, Beli P, Tiwari VK.

Nat Commun. 2017 Nov 15;8(1):1523. doi: 10.1038/s41467-017-01366-x.

5.

Inducible knockdown of procollagen I protects mice from liver fibrosis and leads to dysregulated matrix genes and attenuated inflammation.

Molokanova O, Schönig K, Weng SY, Wang X, Bros M, Diken M, Ohngemach S, Karsdal M, Strand D, Nikolaev A, Eshkind L, Schuppan D.

Matrix Biol. 2018 Mar;66:34-49. doi: 10.1016/j.matbio.2017.11.002. Epub 2017 Nov 6.

PMID:
29122677
6.

Improvement of In Vivo Expression of Genes Delivered by Self-Amplifying RNA Using Vaccinia Virus Immune Evasion Proteins.

Beissert T, Koste L, Perkovic M, Walzer KC, Erbar S, Selmi A, Diken M, Kreiter S, Türeci Ö, Sahin U.

Hum Gene Ther. 2017 Dec;28(12):1138-1146. doi: 10.1089/hum.2017.121. Epub 2017 Sep 6.

7.

CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.

Kranz LM, Beck JD, Grunwitz C, Hotz C, Vormehr M, Diken M.

Hum Vaccin Immunother. 2017 Oct 3;13(10):2272-2279. doi: 10.1080/21645515.2017.1358327. No abstract available.

8.

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.

Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, Omokoko T, Vormehr M, Albrecht C, Paruzynski A, Kuhn AN, Buck J, Heesch S, Schreeb KH, Müller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Rae R, Breitkreuz A, Tolliver C, Suchan M, Martic G, Hohberger A, Sorn P, Diekmann J, Ciesla J, Waksmann O, Brück AK, Witt M, Zillgen M, Rothermel A, Kasemann B, Langer D, Bolte S, Diken M, Kreiter S, Nemecek R, Gebhardt C, Grabbe S, Höller C, Utikal J, Huber C, Loquai C, Türeci Ö.

Nature. 2017 Jul 13;547(7662):222-226. doi: 10.1038/nature23003. Epub 2017 Jul 5.

PMID:
28678784
9.

1-ethyl-3-(6-methylphenanthridine-8-il) urea modulates TLR3/9 activation and induces selective pro-inflammatory cytokine expression in vitro.

Teofilović NK, Bihi M, Stojković MR, Tumir LM, Ester K, Kralj M, Majhen D, Oršolić N, Lepur A, Vrbanec D, Markotić A, Dembić Z, Weber AN, Piantanida I, Vugrek O, Diken M, Knežević J.

Bioorg Med Chem Lett. 2017 Apr 1;27(7):1530-1537. doi: 10.1016/j.bmcl.2017.02.048. Epub 2017 Feb 20.

PMID:
28254484
10.

Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome.

Diken M, Vormehr M, Grunwitz C, Kreiter S, Türeci Ö, Sahin U.

Methods Mol Biol. 2017;1499:223-236.

PMID:
27987153
11.

SiRNA-mediated in vivo gene knockdown by acid-degradable cationic nanohydrogel particles.

Leber N, Kaps L, Aslam M, Schupp J, Brose A, Schäffel D, Fischer K, Diken M, Strand D, Koynov K, Tuettenberg A, Nuhn L, Zentel R, Schuppan D.

J Control Release. 2017 Feb 28;248:10-23. doi: 10.1016/j.jconrel.2016.12.006. Epub 2016 Dec 9.

PMID:
27940184
12.

mRNA: A Versatile Molecule for Cancer Vaccines.

Diken M, Kranz LM, Kreiter S, Sahin U.

Curr Issues Mol Biol. 2017;22:113-128. Epub 2016 Nov 1. Review.

PMID:
27801664
13.

Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma.

Grabbe S, Haas H, Diken M, Kranz LM, Langguth P, Sahin U.

Nanomedicine (Lond). 2016 Oct;11(20):2723-2734. Review.

PMID:
27700619
14.

Harnessing the potential of noninvasive in vivo preclinical imaging of the immune system: challenges and prospects.

Diken M, Pektor S, Miederer M.

Nanomedicine (Lond). 2016 Oct;11(20):2711-2722. Epub 2016 Sep 15. Review.

PMID:
27628499
15.

Vaccination with trifunctional nanoparticles that address CD8+ dendritic cells inhibits growth of established melanoma.

Shen L, Krauthäuser S, Fischer K, Hobernik D, Abassi Y, Dzionek A, Nikolaev A, Voltz N, Diken M, Krummen M, Montermann E, Tubbe I, Lorenz S, Strand D, Schild H, Grabbe S, Bros M.

Nanomedicine (Lond). 2016 Oct;11(20):2647-2662. Epub 2016 Sep 15.

PMID:
27628310
16.

Dextran-based therapeutic nanoparticles for hepatic drug delivery.

Foerster F, Bamberger D, Schupp J, Weilbächer M, Kaps L, Strobl S, Radi L, Diken M, Strand D, Tuettenberg A, Wich PR, Schuppan D.

Nanomedicine (Lond). 2016 Oct;11(20):2663-2677. Epub 2016 Sep 15.

PMID:
27628057
17.

CIMT 2016: Mechanisms of efficacy in cancer immunotherapy - Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10-12 2016, Mainz, Germany.

Kranz LM, Birtel M, Hilscher L, Grunwitz C, Petschenka J, Vascotto F, Vormehr M, Voss RH, Kreiter S, Diken M.

Hum Vaccin Immunother. 2016 Nov;12(11):2805-2812. Epub 2016 Jul 19. No abstract available.

18.

Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice.

Selmi A, Vascotto F, Kautz-Neu K, Türeci Ö, Sahin U, von Stebut E, Diken M, Kreiter S.

Cancer Immunol Immunother. 2016 Sep;65(9):1075-83. doi: 10.1007/s00262-016-1869-7. Epub 2016 Jul 15.

PMID:
27422115
19.

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.

Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, Grunwitz C, Vormehr M, Hüsemann Y, Selmi A, Kuhn AN, Buck J, Derhovanessian E, Rae R, Attig S, Diekmann J, Jabulowsky RA, Heesch S, Hassel J, Langguth P, Grabbe S, Huber C, Türeci Ö, Sahin U.

Nature. 2016 Jun 16;534(7607):396-401. doi: 10.1038/nature18300. Epub 2016 Jun 1.

PMID:
27281205
20.

FLT3 Ligand as a Molecular Adjuvant for Naked RNA Vaccines.

Kreiter S, Diken M, Selmi A, Petschenka J, Türeci Ö, Sahin U.

Methods Mol Biol. 2016;1428:163-75. doi: 10.1007/978-1-4939-3625-0_11.

PMID:
27236799
21.

Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines.

Türeci Ö, Vormehr M, Diken M, Kreiter S, Huber C, Sahin U.

Clin Cancer Res. 2016 Apr 15;22(8):1885-96. doi: 10.1158/1078-0432.CCR-15-1509. Review.

22.

Reductive Decationizable Block Copolymers for Stimuli-Responsive mRNA Delivery.

Nuhn L, Kaps L, Diken M, Schuppan D, Zentel R.

Macromol Rapid Commun. 2016 Jun;37(11):924-33. doi: 10.1002/marc.201600046. Epub 2016 Apr 14.

PMID:
27075781
23.

RNA Vaccination Therapy: Advances in an Emerging Field.

Kreiter S, Diken M, Pascolo S, Nair SK, Thielemans KM, Geall A.

J Immunol Res. 2016;2016:9703914. doi: 10.1155/2016/9703914. Epub 2016 Feb 25. No abstract available.

24.

Actively personalized cancer vaccines--the step into clinical application.

Kloke BP, Kreiter S, Vormehr M, Diken M, Kuhn AN, Sahin U.

Pharmazie. 2016 Jan;71(1):43-7. Review.

PMID:
26867352
25.

Mutanome directed cancer immunotherapy.

Vormehr M, Diken M, Boegel S, Kreiter S, Türeci Ö, Sahin U.

Curr Opin Immunol. 2016 Apr;39:14-22. doi: 10.1016/j.coi.2015.12.001. Epub 2015 Dec 21. Review.

PMID:
26716729
26.

Current Developments in Actively Personalized Cancer Vaccination with a Focus on RNA as the Drug Format.

Diken M, Kreiter S, Kloke B, Sahin U.

Prog Tumor Res. 2015;42:44-54. doi: 10.1159/000437184. Epub 2015 Sep 4. Review.

PMID:
26383626
27.

CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy.

Kranz LM, Birtel M, Krienke C, Grunwitz C, Petschenka J, Reuter KC, van de Roemer N, Vascotto F, Vormehr M, Kreiter S, Diken M.

Hum Vaccin Immunother. 2016;12(1):213-21. doi: 10.1080/21645515.2015.1068485. Epub 2015 Jul 17. No abstract available.

28.

Specific hepatic delivery of procollagen α1(I) small interfering RNA in lipid-like nanoparticles resolves liver fibrosis.

Jiménez Calvente C, Sehgal A, Popov Y, Kim YO, Zevallos V, Sahin U, Diken M, Schuppan D.

Hepatology. 2015 Oct;62(4):1285-97. doi: 10.1002/hep.27936. Epub 2015 Aug 28.

29.

Erratum: Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, Tadmor AD, Schoenberger SP, Huber C, Türeci Ö, Sahin U.

Nature. 2015 Jul 16;523(7560):370. doi: 10.1038/nature14567. Epub 2015 Jun 3. No abstract available.

PMID:
26040715
30.

Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, Tadmor AD, Schoenberger SP, Huber C, Türeci Ö, Sahin U.

Nature. 2015 Apr 30;520(7549):692-6. doi: 10.1038/nature14426. Epub 2015 Apr 22. Erratum in: Nature. 2015 Jul 16;523(7560):370.

31.

Tailoring the stealth properties of biocompatible polysaccharide nanocontainers.

Kang B, Okwieka P, Schöttler S, Seifert O, Kontermann RE, Pfizenmaier K, Musyanovych A, Meyer R, Diken M, Sahin U, Mailänder V, Wurm FR, Landfester K.

Biomaterials. 2015 May;49:125-34. doi: 10.1016/j.biomaterials.2015.01.042. Epub 2015 Feb 16.

PMID:
25725561
32.

CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.

Diken M, Boegel S, Grunwitz C, Kranz LM, Reuter K, van de Roemer N, Vascotto F, Vormehr M, Kreiter S.

Hum Vaccin Immunother. 2014;10(10):3090-100. doi: 10.4161/hv.29767. No abstract available.

33.

Enhanced in vivo targeting of murine nonparenchymal liver cells with monophosphoryl lipid A functionalized microcapsules.

Pietrzak-Nguyen A, Fichter M, Dedters M, Pretsch L, Gregory SH, Meyer C, Doganci A, Diken M, Landfester K, Baier G, Gehring S.

Biomacromolecules. 2014 Jul 14;15(7):2378-88. doi: 10.1021/bm5006728. Epub 2014 Jun 26.

PMID:
24901387
34.

mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA.

Diken M, Kreiter S, Vascotto F, Selmi A, Attig S, Diekmann J, Huber C, Türeci Ö, Sahin U.

Cancer Immunol Res. 2013 Dec;1(6):386-92. doi: 10.1158/2326-6066.CIR-13-0046. Epub 2013 Sep 20.

35.

Mutated tumor alleles are expressed according to their DNA frequency.

Castle JC, Loewer M, Boegel S, Tadmor AD, Boisguerin V, de Graaf J, Paret C, Diken M, Kreiter S, Türeci Ö, Sahin U.

Sci Rep. 2014 Apr 22;4:4743. doi: 10.1038/srep04743.

36.

Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma.

Castle JC, Loewer M, Boegel S, de Graaf J, Bender C, Tadmor AD, Boisguerin V, Bukur T, Sorn P, Paret C, Diken M, Kreiter S, Türeci Ö, Sahin U.

BMC Genomics. 2014 Mar 13;15:190. doi: 10.1186/1471-2164-15-190.

37.

CIMT 2013: advancing targeted therapies--report on the 11th Annual Meeting of the Association for Cancer Immunotherapy, May 14-16 2013, Mainz, Germany.

Diken M, Attig S, Grunwitz C, Kranz L, Simon P, van de Roemer N, Vascotto F, Kreiter S.

Hum Vaccin Immunother. 2013 Sep;9(9):2025-32. doi: 10.4161/hv.25768. Epub 2013 Jul 22.

38.

In vivo molecular imaging with cetuximab, an anti-EGFR antibody, for prediction of response in xenograft models of human colorectal cancer.

Goetz M, Hoetker MS, Diken M, Galle PR, Kiesslich R.

Endoscopy. 2013 Jun;45(6):469-77. doi: 10.1055/s-0032-1326361. Epub 2013 Apr 11.

PMID:
23580409
39.

Antitumor vaccination with synthetic mRNA: strategies for in vitro and in vivo preclinical studies.

Diken M, Kreiter S, Selmi A, Türeci O, Sahin U.

Methods Mol Biol. 2013;969:235-46. doi: 10.1007/978-1-62703-260-5_15. Review.

PMID:
23296938
40.

HLA typing from RNA-Seq sequence reads.

Boegel S, Löwer M, Schäfer M, Bukur T, de Graaf J, Boisguérin V, Türeci O, Diken M, Castle JC, Sahin U.

Genome Med. 2012 Dec 22;4(12):102. doi: 10.1186/gm403. eCollection 2012.

41.

Confidence-based somatic mutation evaluation and prioritization.

Löwer M, Renard BY, de Graaf J, Wagner M, Paret C, Kneip C, Türeci O, Diken M, Britten C, Kreiter S, Koslowski M, Castle JC, Sahin U.

PLoS Comput Biol. 2012;8(9):e1002714. doi: 10.1371/journal.pcbi.1002714. Epub 2012 Sep 27.

42.

Molecular in vivo imaging of gastric cancer in a human-murine xenograft model: targeting epidermal growth factor receptor.

Hoetker MS, Kiesslich R, Diken M, Moehler M, Galle PR, Li Y, Goetz M.

Gastrointest Endosc. 2012 Sep;76(3):612-20. doi: 10.1016/j.gie.2012.05.013. Epub 2012 Jul 7.

PMID:
22771099
43.

Exploiting the mutanome for tumor vaccination.

Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C, Koslowski M, Kuhn AN, Britten CM, Huber C, Türeci O, Sahin U.

Cancer Res. 2012 Mar 1;72(5):1081-91. doi: 10.1158/0008-5472.CAN-11-3722. Epub 2012 Jan 11.

44.

FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines.

Kreiter S, Diken M, Selmi A, Diekmann J, Attig S, Hüsemann Y, Koslowski M, Huber C, Türeci Ö, Sahin U.

Cancer Res. 2011 Oct 1;71(19):6132-42. doi: 10.1158/0008-5472.CAN-11-0291. Epub 2011 Aug 4.

45.

Tumor vaccination using messenger RNA: prospects of a future therapy.

Kreiter S, Diken M, Selmi A, Türeci Ö, Sahin U.

Curr Opin Immunol. 2011 Jun;23(3):399-406. doi: 10.1016/j.coi.2011.03.007. Epub 2011 Apr 13. Review.

PMID:
21497074
46.

Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation.

Diken M, Kreiter S, Selmi A, Britten CM, Huber C, Türeci Ö, Sahin U.

Gene Ther. 2011 Jul;18(7):702-8. doi: 10.1038/gt.2011.17. Epub 2011 Mar 3.

PMID:
21368901
47.

Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics.

Kuhn AN, Diken M, Kreiter S, Vallazza B, Türeci Ö, Sahin U.

RNA Biol. 2011 Jan-Feb;8(1):35-43. Epub 2011 Jan 1.

PMID:
21289486
48.

Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.

Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Türeci O, Sahin U.

Cancer Res. 2010 Nov 15;70(22):9031-40. doi: 10.1158/0008-5472.CAN-10-0699. Epub 2010 Nov 2.

49.

Tetracycline-controlled transgene activation using the ROSA26-iM2-GFP knock-in mouse strain permits GFP monitoring of DOX-regulated transgene-expression.

Wörtge S, Eshkind L, Cabezas-Wallscheid N, Lakaye B, Kim J, Heck R, Abassi Y, Diken M, Sprengel R, Bockamp E.

BMC Dev Biol. 2010 Sep 3;10:95. doi: 10.1186/1471-213X-10-95.

50.

Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo.

Kuhn AN, Diken M, Kreiter S, Selmi A, Kowalska J, Jemielity J, Darzynkiewicz E, Huber C, Türeci O, Sahin U.

Gene Ther. 2010 Aug;17(8):961-71. doi: 10.1038/gt.2010.52. Epub 2010 Apr 22.

PMID:
20410931

Supplemental Content

Support Center